Table 2 Hemophilia-related clinical outcomes before and 6 months after implementing moderate- to vigorous-intensity physical activity protocol during low-dose PK-guided EHL FVIII prophylaxis

Subgroup by age

≤ 15 years (n = 4)

9 (1–16)

2 (0–5)

0.09

> 15 years (n = 9)

10 (4–14)

4 (4–6)

0.049

Subgroup by target joints

Present (n = 10)

10 (3–14)

4 (2–6)

0.04

Absent (n = 3)

16 (0–16)

4 (0–6)

0.17

AJBR

All patients (N = 13)

4 (0–12)

2 (0–4)

0.03

Subgroup by age

≤ 15 years (n = 4)

0 (0–0)

0 (0–0)

NS

> 15 years (n = 9)

10 (4–13)

4 (2–6)

0.03

Subgroup by target joints

Present (n = 10)

10 (2–13)

4 (0–6)

0.03

Absent (n = 3)

0 (0–0)

0 (0–0)

NS

HJHS

All patients (N = 13)

14 (10–24)

11 (8–16)

0.003

Subgroup by age

≤ 15 years (n = 4)

1 (0–6)

1 (0–5)

0.32

> 15 years (n = 9)

21 (14–28)

14 (11–20)

0.007

Subgroup by target joints

Present (n = 10)

20.5 (14–28)

14 (8–20)

0.005

Absent (n = 3)

0 (0–2)

0 (0–2)

0.99

QoL scores

All patients (N = 13)

61(48–80)

54 (40–68)

0.001

Subgroup by age

≤ 15 years (n = 4)

55.5 (37.5–72.5)

49.5 (29.5–64)

0.01

> 15 years (n = 9)

62 (48–80)

54 (40–68)

0.008

Subgroup by target joints

Present (n = 10)

61.5 (41–80)

53 (36–68)

< 0.001

Absent (n = 3)

61 (50–84)

56 (43–72)

0.06

Skeletal muscle mass (kg)

All patients (N = 13)

22.3 (19.6–24.8)

22.6 (20.5–25.1)

0.001

Subgroup by age

≤ 15 years (n = 4)

18.1 (14.4–26.1)

19.2 (15.0–27.7)

0.06

> 15 years (n = 9)

22.5 (21.6–24.8)

22.7 (21.7–25.1)

0.008

Subgroup by target joints

Present (n = 10)

22.7 (21.6–25.2)

23.1 (21.7–25.5)

0.005

Absent (n = 3)

16.6 (12.2–19.6)

17.7 (12.3–20.7)

0.10